{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-032070","form_type":"8-K","ticker":"HROW","cik":"0001360214","company_name":"HARROW, INC.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.320379+00:00","generated_at":"2026-06-21T19:43:29.705609+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Harrow Q3 revenue up 22% to $22.8M; FDA approves IHEEZO, narrows net loss","bullets":["Revenue $22.8M (+22% YoY); net loss narrowed to $6.5M from $8.3M; adjusted EBITDA $2.5M vs. -$0.1M.","FDA approved IHEEZO (ocular anesthetic NDA) on Sept 27; launch expected to double revenues within 24 months.","Launched Fortisite (fortified antibiotics) and atropine.com; sold non-ophthalmic product line to become pure-play.","Core net loss per share ($0.06) improved from ($0.20); revenue per shipping day $355K (+21%).","Nearly $1M order backlog at quarter end due to supply chain issues; cleared in Q4; scaling production."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-032070","json":"https://secwatch.observer/filing/0001493152-22-032070.json","markdown":"https://secwatch.observer/filing/0001493152-22-032070.md","text":"https://secwatch.observer/filing/0001493152-22-032070.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1360214/000149315222032070/0001493152-22-032070-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1360214/000149315222032070/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T19:43:29.705609+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"991f8cb802a5ba6b01211e7d2671877691a77403","claim":"HARROW, INC. reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"On November 14, 2022, Harrow Health, Inc. (the “Company”) issued a press release and a letter to stockholders announcing its financial results for the period ended September 30, 2022 and an update on recent corporate events.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1360214/000149315222032070/0001493152-22-032070-index.htm","confidence":0.97,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}